Eli Lilly allies itself with Alzheimer's institute in phase III dementia drug trials

Banner Alzheimer's Institute will assist Eli Lilly in its phase III study of the company's Alzheimer's treatment, donanemab.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY RITZAU FINANS AND ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Eli Lilly has announced a collaboration with Banner Alzheimer's Institute, which specializes in early identification and tracking of the disease, over a phase III trial of its drug donanemab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading